Clinical observation of 125I-labeled anti-alpha fetoprotein antibody radioimmunotherapy in hepatocellular carcinoma

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 3, Issue 1

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

170

HTML

1827

Figures (1-4)

157

Tables (1-3)

134

Sum=2288

Mar 15, 1997 (publication date) through Apr 25, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Original Research

World J Gastroenterol. Mar 15, 1997; 3(1): 43-46
Published online Mar 15, 1997. doi: 10.3748/wjg.v3.i1.43

Table 2 Dose, cycle (times) number of 125I group and control (A, B, C) groups

Treatment program	¹²⁵I		A		B	C
Treatment program	I	≥ II	I	≥ II		I	≥ II
Targeted times, treatment (case)	6	16	8	17
Average/case (MBq)	163.5	382	388.5	984.9	treatment for 20-50 d
Median/case (MBq)	207.2p	340.4	392.2	936.1
Chemotherapy (case)	7	5	11	6	2	0	25¹
Including TAI, E (case)	7	3	4	1	2	13	3

¹25 cases treated by 2 cycles, among them 13 cases had once of TAI.

Citation: Wu YD, Yang KZ, Zhou DN, Gang YQ, Song XQ, Hu XH, Huang BY. Clinical observation of ¹²⁵I-labeled anti-alpha fetoprotein antibody radioimmunotherapy in hepatocellular carcinoma. World J Gastroenterol 1997; 3(1): 43-46
URL: https://www.wjgnet.com/1007-9327/full/v3/i1/43.htm
DOI: https://dx.doi.org/10.3748/wjg.v3.i1.43